TD Cowen analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...